Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HBV Inhibitor
BAY39-5493 is a non-nucleoside inhibitor targeting hepatitis B virus (HBV) replication. It exerts its biological activity by blocking the formation of viral core particles, thereby inhibiting viral DNA replication. With an IC50 value of 0.03 μM against HBV in stably transfected HepG2.2.15 cells, BAY39-5493 serves as a valuable tool for research in the field of antiviral therapeutics and HBV biology. -
HBV Inhibitor
BAY38-7690 is a non-nucleoside inhibitor that specifically targets hepatitis B virus (HBV) replication. It functions by obstructing the assembly of viral core particles, thereby inhibiting viral DNA replication. With an IC50 value of 0.15 μM in stably transfected HepG2.2.15 cells, BAY38-7690 is an important tool for investigating HBV biology and evaluating potential therapeutic strategies against hepatitis B virus infections. -
HBV Inhibitor
Personalised postprandial-targeting is an HBV inhibitor that modulates water-heme interactions, specifically targeting low-spin cytochrome P450 complexes. This reagent effectively preserves the axial water ligands of CYP2C9, even when inhibitors are present, enabling advanced studies of enzyme dynamics. Additionally, it facilitates the observation of hydrogen atoms in the axial water ligands through EPR spectroscopy, offering valuable insights into the active site of the enzyme, making it a critical tool for research in enzymology and drug development. -
HBV Inhibitor
GS-8873 TFA is a potent inhibitor of hepatitis B virus (HBV) surface antigen (HBsAg) production, exhibiting an EC50 value of 4 nM. This orally bioavailable compound demonstrates favorable pharmacokinetic properties in rodent models and metabolic stability in human hepatocytes. Notably, GS-8873 TFA has been associated with neurofunctional deficits in both rats and cynomolgus monkeys, making it a valuable tool for research in HBV therapies and associated neurological effects. -
Nucleotide Reverse Transcriptase Inhibitor
Tenofovir disoproxil aspartate is a nucleotide reverse transcriptase inhibitor primarily targeting HIV and chronic Hepatitis B. It demonstrates potent antiviral activity by interfering with viral RNA replication, ultimately leading to reduced viral load in infected patients. This compound is essential in research aimed at developing effective therapeutic strategies against retroviral infections. -
HCV/SARS-CoV-2 Inhibitor
Bemnifosbuvir is a potent inhibitor of Hepatitis C virus (HCV) replication with demonstrated efficacy against SARS-CoV-2. This orally active compound exhibits significant antiviral activity in vitro, achieving an effective concentration (EC90) of 0.47 μM against COVID-19. Bemnifosbuvir displays pangenotypic activity, making it a valuable tool for research into antiviral therapies for both HCV and SARS-CoV-2 infections. -
HCV/SARS-CoV-2 Inhibitor
Bemnifosbuvir hemisulfate is a potent inhibitor of HCV viral replication and a promising antiviral agent against SARS-CoV-2. This guanosine nucleotide proagent exhibits significant efficacy in vitro, demonstrating an EC90 value of 0.47 μM against COVID-19. Bemnifosbuvir hemisulfate also shows pangenotypic antiviral activity, making it a valuable tool for research in viral infections and therapeutic development. -
HCV/HIV Inhibitor
C5A is a microbicidal peptide that targets and inhibits both hepatitis C virus (HCV) and human immunodeficiency virus (HIV). By disrupting the membrane integrity of the HIV virion and affecting the conical capsid core that encases the viral genome, C5A significantly reduces the infectivity of a wide range of HIV isolates in various primary target cells in vitro. Additionally, studies have demonstrated that C5A offers protective effects in mice against vaginal and rectal challenges with HIV, highlighting its potential utility in antiviral research applications. -
COVID-19 Inhibitor
RBT-9 is a COVID-19 inhibitor that targets viral replication and inflammation pathways. It has demonstrated efficacy in preventing the progression to severe COVID-19 and associated organ failure. Furthermore, RBT-9 exhibits antiviral activity against various enveloped viruses, including influenza, hepatitis C virus (HCV), dengue, and yellow fever, making it a valuable tool for research in viral pathogenesis and therapeutic intervention. -
Serine β-Lactamase Inhibitor
Pilabactam is a potent covalent inhibitor of serine β-lactamases, exhibiting IC50 values between 1 nM and 175 nM across various serine β-lactamase types. This compound significantly enhances the efficacy of β-lactam antibiotics against challenging pathogens such as Carbapenem-Resistant Enterobacterales (CRE) and Acinetobacter baumannii (CRAB). Pilabactam is valuable in research focused on bacterial infections and antibiotic resistance mechanisms. -
Bacterial Inhibitor
Pyrroxamycin is a novel antibiotic with a primary mechanism targeting Gram-positive bacteria and dermatophytes. Derived from the fermentation of Streptomyces, it exhibits potent antibacterial activity. This compound has potential applications in pharmaceutical research for the development of new antimicrobials, particularly against resistant bacterial strains. Detailed analysis of its chemical structure was performed using X-ray crystallography and 13C NMR spectroscopy, elucidating its physicochemical properties and enhancing its utility in microbiological studies. -
Quorum Sensing Inhibitor
Aculene D is a quorum sensing inhibitor derived from fungal metabolites that targets the signaling mechanisms in bacteria. It effectively reduces violacein production in Chromobacterium violaceum CV026 cultures induced by N-hexanoyl-L-homoserine lactone (C6-HSL) at sub-inhibitory concentrations. This compound is valuable for research exploring bacterial communication and the modulation of biofilm formation, with potential applications in combating antibiotic resistance and developing new antimicrobial strategies. -
β-lactamase Inhibitor
β-Lactamase-IN-5 is a potent β-lactamase inhibitor that serves to enhance the efficacy of β-lactam antibiotics against resistant bacterial strains. Its primary mechanism involves the inhibition of β-lactamase enzymes, which are responsible for antibiotic resistance. This compound is valuable for research applications aimed at understanding and combating bacterial infections, particularly those caused by multidrug-resistant pathogens. -
Bacterial Inhibitor
β-Lactamase-IN-6 is a potent inhibitor of β-Lactamase enzymes, which play a crucial role in bacterial resistance to β-lactam antibiotics. This compound demonstrates significant antibacterial activity by preventing the enzymatic breakdown of β-lactam antibiotics, thereby enhancing their effectiveness against resistant bacterial strains. β-Lactamase-IN-6 serves as a valuable tool in microbiological research and antibiotic development, providing insights into combating bacterial infections and resistance mechanisms. -
Bacterial Inhibitor
(R)-Gyramide A hydrochloride is a bacterial DNA gyrase inhibitor that effectively disrupts DNA supercoiling, exhibiting an IC50 of 3.3 µM. This compound demonstrates significant antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Salmonella enterica, with minimum inhibitory concentrations ranging from 10 to 80 µM. Notably, (R)-Gyramide A hydrochloride does not inhibit topoisomerase IV, making it a valuable tool for studying bacterial mechanisms and antibiotic resistance. -
Bacterial Inhibitor
Acrisorcin is a topical anti-infective compound that functions primarily as a bacterial inhibitor. It exhibits potent fungicidal properties, making it valuable for research into antifungal therapies and the understanding of bacterial resistance mechanisms. Its efficacy in mitigating fungal infections supports its application in various microbiological studies and therapeutic evaluations. -
Bacterial Inhibitor
CID21480113 is an inhibitor targeting bacterial pathways, specifically effective against dapsone-resistant strains of leprosy. This compound demonstrates significant antibacterial activity, making it a valuable tool for research in microbial resistance and infectious disease studies. Its ability to combat resistant bacteria positions CID21480113 as a relevant reagent for investigations into alternative therapies for leprosy. -
Bacterial Inhibitor
o-Cymen-5-ol acts as a broad-spectrum antimicrobial agent targeting various bacterial and fungal pathogens. It demonstrates effective minimum inhibitory concentrations (MICs) against organisms such as Streptococcus mutans and Candida albicans. Notably, o-Cymen-5-ol exhibits synergistic effects when combined with zinc, enhancing its antimicrobial activity against oral pathogens by inhibiting glycolysis. Studies indicate a more pronounced antibacterial effect in formulations such as toothpaste compared to placebo. This compound is valuable for research applications in microbiology and dental health. -
Bacterial Inhibitor
Strinoline is a bacterial inhibitor that targets and disrupts bacterial cell function. This compound exhibits significant antibacterial activity, making it a valuable tool for research in the field of microbiology. Strinoline can be utilized to study bacterial resistance mechanisms and the efficacy of antibiotic therapies. -
Bacterial IMPDH Inhibitor
IMPDH-IN-1 is a selective inhibitor of bacterial inosine 5'-monophosphate dehydrogenase (IMPDH), targeting the catalytic domain of the enzyme. This compound demonstrates potent inhibitory activity against IMPDH from key bacterial pathogens, including Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli. It serves as a valuable tool for research into bacterial metabolism and the development of novel antimicrobial therapies. -
Bacterial Inhibitor
4-Hydroxysphinganine (C17 base) is a bacterial inhibitor that plays a critical role in membrane structure for various organisms, including fungi, plants, and bacteria. It is essential for maintaining membrane integrity, regulating cellular growth, and facilitating the heat stress response in yeast. Additionally, 4-Hydroxysphinganine acts as a precursor for the synthesis of key lipid mediators, such as PHS 1-phosphate and inositol phosphorylceramide. Its properties also support keratinocyte differentiation, making it relevant for applications in dermatology and cosmetic research. -
Bacterial Inhibitor
Sarothralin G is a potent antibacterial compound derived from Hypericum japonicum Thunb. It exhibits exceptional activity against Gram-positive bacteria, including Staphylococcus aureus, Bacillus subtilis, and Nocardia species. With its unique phenolic and aromatic acid structure, Sarothralin G demonstrates superior antibacterial efficacy compared to related compounds such as Sarothralen A, B and Saroaspidin A, B, C. This compound is valuable for research in antibiotic development and the study of bacterial resistance mechanisms. -
AgrA Quorum-sensing Inhibitor
Apicidin D2 is a specific inhibitor of the accessory gene regulator A (AgrA), which plays a pivotal role in bacterial quorum sensing. This fungal metabolite demonstrates notable anti-virulence properties by effectively suppressing AgrA activation in Staphylococcus aureus, including methicillin-resistant strains (MRSA), without exhibiting biocidal effects. Apicidin D2 is a valuable reagent for research focused on understanding MRSA infections and developing strategies to combat quorum-sensing related pathogenicity. -
Bacterial Inhibitor
INF55 is a multidrug resistance pump inhibitor targeting bacterial efflux mechanisms. By inhibiting the NoA pump, INF55 enhances the antibacterial efficacy of compounds such as berberine, reducing their efflux and overcoming bacterial resistance. Structural variants of INF55 demonstrate diverse NoA inhibitory activities, which can influence the antibacterial effectiveness of their respective heterocomplexes. This versatility makes INF55 and its derivatives valuable tools in the study and development of novel antimicrobial strategies. -
Bacterial Inhibitor
Racemomycin B is a potent bacterial inhibitor derived from Streptomyces lavendulae OP-2, characterized as a streptothricin antibiotic with three β-lysine groups. It demonstrates significant antimicrobial activity against plant pathogenic microorganisms, effectively inhibiting the root growth of Brassica rapa L. at a concentration of 50 ppm. Racemomycin B exhibits a minimum inhibitory concentration (MIC) of 0.4 μg/ml against Pseudomonas syringae pv. tabaci IFO-3508 and a MIC range of 0.1-2.0 μg/ml against various strains of Fusarium oxysporum. The biological efficacy of this compound is enhanced by the increasing number of β-lysine groups, making it a valuable tool for agricultural research. -
Bacterial Inhibitor
(R,R)-Ethambutol is a bacterial inhibitor primarily targeting Mycobacterium tuberculosis, exhibiting significant antituberculosis activity. It is commonly utilized in combination therapies to enhance the therapeutic efficacy against tuberculosis. Additionally, (R,R)-Ethambutol demonstrates effectiveness in inhibiting infections caused by Mycobacterium avium complex and Mycobacterium kansasii, making it a valuable reagent for research in mycobacterial infections. -
β-lactamase Inhibitor
CB-618 is a β-lactamase inhibitor that reversibly covalently interacts with Ambler class A, C, and select class D serine β-lactamases. While it exhibits limited antibacterial activity on its own, CB-618 notably enhances the effectiveness of Meropenem against enzyme-producing Enterobacteriaceae. This compound is a valuable tool for research focused on combating drug-resistant bacterial strains. -
β-Lactamase Inhibitor
LN-1-255 sodium is a β-lactamase inhibitor designed to effectively combat resistance in bacteria. It exhibits a broad-spectrum inhibitory effect on type D carbapenemases, demonstrating an IC50 of 3 nM against OXA-48, while also showing strong activity against OXA-23 and OXA-24/40. The compound enhances the efficacy of carbapenem antibiotics through a synergistic mechanism. LN-1-255 sodium is a valuable tool for researching the challenges posed by carbapenem-hydrolyzing class D β-lactamases (CHDLs) in bacterial resistance. -
Bacterial Inhibitor
Fenvalerate-d6 is a deuterium-labeled derivative of Fenvalerate, primarily targeting bacterial inhibition. This compound exhibits potent antibacterial activity, making it valuable for research applications focused on elucidating bacterial resistance mechanisms and evaluating the efficacy of antibacterial agents. Its isotopic labeling enables tracking and quantification in metabolic studies and pharmacokinetic investigations. -
Bacterial Inhibitor
(E/Z)-Aureusidin is a flavonoid compound that functions as a bacterial inhibitor through its antioxidant properties. It effectively inhibits the production of reactive oxygen species, thereby reducing cellular damage and inflammation by lowering the expression of inflammatory factors. Additionally, (E/Z)-Aureusidin exhibits broad-spectrum antimicrobial activity, highlighting its potential applications in combating bacterial infections and studying inflammatory responses. -
Bacterial Inhibitor
AGS1286 sodium, an organosulfur compound, functions as a bacterial inhibitor by targeting enzymatic activities and metabolic pathways influenced by sulfur-containing compounds. This reagent is utilized in research to examine the regulatory effects on bacterial growth and gene expression, making it valuable for studies in microbiology and metabolic regulation. Its unique structural features provide insights into the role of sulfur in microbial dynamics and enzymatic processes. -
Bacterial Inhibitor
VCC234718 is a selective inhibitor of inosine monophosphate dehydrogenase (GuaB2), effectively targeting Mycobacterium tuberculosis (Mtb) to inhibit its growth. With a K value of 100 nM, VCC234718 exhibits non-competitive inhibition involving both IMP and NAD+, demonstrating its ability to disrupt enzymatic function through direct interactions with these metabolites. This compound is valuable for studying mycobacterial infections and developing new treatments for tuberculosis. -
Bacterial Inhibitor
Antitubercular agent-47 (compound 5C) is a potent bacterial inhibitor specifically targeting Mycobacterium tuberculosis. It demonstrates significant efficacy against drug-sensitive (DS), multidrug-resistant (MDR), and extensively drug-resistant (XDR) clinical isolates. This compound is valuable for research applications focused on tuberculosis treatment and drug resistance mechanisms. -
LasB Inhibitor, Antibacterial Activity
Elastase LasB-IN-1 is a selective inhibitor of elastase LasB, exhibiting a potent IC50 value of 76 nM. This compound demonstrates significant antibacterial activity, making it an important tool for research applications focused on bacterial infections. Its specificity for LasB facilitates investigations into the role of elastolytic enzymes in microbial pathogenesis. -
Bacterial Inhibitor
Antibacterial agent 149 is a potent laccase inhibitor that exhibits significant antibacterial properties. This compound is particularly effective against bacterial pathogens and has demonstrated high fungicidal activity, making it a valuable tool for studying rice sheath blight and related diseases. Its mechanism of action and specificity enhance its utility in researching bacterial inhibition and plant pathogenic interactions. -
Bacterial Inhibitor
15-Methylhexadeca Sphinganine is an iso-branched sphingolipid that acts as a bacterial inhibitor. It is identified as a component of ceramide-containing phospholipids in bacterial cell membranes. This compound is valuable for research applications focused on understanding bacterial lipid metabolism and exploring potential therapeutic strategies against bacterial infections. -
Bacterial Inhibitor
Chevalone B is a bacterial inhibitor derived from the marine sponge-associated fungus Aspergillus similanensis. It exhibits antimicrobial activity against both Gram-positive and Gram-negative bacteria, as well as Candida albicans and multidrug-resistant environmental strains. Its potential applications in antimicrobial research highlight its significance in the development of novel therapeutic agents. -
Beta-lactamase Inhibitor
Relebactam sodium is a potent and selective β-lactamase inhibitor that functions to inhibit the enzymatic breakdown of β-lactam antibiotics. By binding to a diverse range of β-lactamases, Relebactam sodium enhances the effectiveness of these antibiotics and delays the emergence of bacterial resistance. This compound is particularly valuable in research focusing on combating complex bacterial infections and improving antibiotic therapeutic options. -
HSV-1 Inhibitor
Cycloviracin B1 is a potent inhibitor of herpes simplex virus type 1 (HSV-1), demonstrating significant antiviral activity against this pathogen. In addition to its primary application in virology, it exhibits weak anti-Gram-positive bacterial activity, which may provide further avenues for research. This compound is valuable for studies focused on HSV-1 infection and potential therapeutic interventions. -
Beta-lactamase Inhibitor
Ent-Avibactam sodium is a β-lactamase inhibitor designed to combat a wide range of bacterial infections. It effectively inhibits Ambler A and C type β-lactamases produced by Enterobacteriaceae, enhancing the efficacy of β-lactam antibiotics like Cefazidime. With an IC50 value significantly lower than other commonly used β-lactamase inhibitors, ent-Avibactam sodium demonstrates superior potency against TEM-1 and P99 enzymes, making it a valuable tool for bacterial resistance research and antibiotic development. -
Bacterial Ribosome Inhibitor
Capreomycin IA is a bactericidal agent that inhibits bacterial ribosomes, primarily affecting mycobacterial species. By blocking the translocation of peptidyl-transfer RNA from the A to the P site, Capreomycin IA effectively interrupts protein synthesis. This compound demonstrates significant antimicrobial activity against Mycobacterium tuberculosis and is useful for research applications related to tuberculosis and other mycobacterial infections. -
Bacterial Inhibitor
Timcodar mesylate is a bacterial efflux pump inhibitor that targets multidrug-resistant strains by directly inhibiting ethidium bromide efflux in Staphylococcus aureus. This compound enhances the effectiveness of antibiotic treatments by reducing the minimum inhibitory concentration required against Gram-positive pathogens, including Staphylococcus aureus, Enterococcus, and Streptococcus pneumoniae. Timcodar mesylate serves as a valuable tool in microbial resistance studies and antibiotic synergy research. -
Bacterial Inhibitor
Anti-MRSA agent 24 is a potent antimicrobial compound specifically targeting methicillin-resistant Staphylococcus aureus (MRSA), with particular efficacy against penicillin-resistant strains. This reagent demonstrates significant antibacterial activity, making it essential for research applications focused on combating resistant bacterial infections and studying mechanisms of antibiotic resistance. -
Bacterial Inhibitor
Streptovitacin A is a potent antibacterial agent derived from microorganisms, designed to inhibit a wide range of bacterial strains and demonstrate antiproliferative effects on tumor cells. Its primary mechanism involves interference with essential bacterial processes, making it a valuable tool in microbiological research and cancer studies. Researchers can utilize Streptovitacin A to explore bacterial resistance mechanisms and evaluate its therapeutic potential in oncology. -
Antibacterial Inhibitor
HA5 is an antibacterial inhibitor that targets biofilm formation in Streptococcus mutans. It demonstrates a potent inhibitory effect with an IC50 value of 6.42 μM, selectively disrupting biofilm structure without impacting bacterial growth. Additionally, HA5 reduces glucan production and extracellular DNA levels, making it a valuable tool for studying bacterial pathogenesis and potential therapeutic interventions in dental caries research. -
Bacterial Inhibitor
7-O-Methylaloeresin A is a 5-methylchromone glycoside isolated from Commiphora socotrana, acting primarily as a bacterial inhibitor. It demonstrates significant antimicrobial activity against methicillin-resistant Staphylococcus aureus (NCTC 11994) and Salmonella typhimurium (ATCC 1255), with minimum inhibitory concentrations (MIC) of 0.72 mM and 0.18 mM, respectively. Additionally, 7-O-Methylaloeresin A exhibits antioxidant properties, with IC50 values of 0.026 mM for the DPPH assay and 0.021 mM for the 2-deoxyribose degradation assay, making it useful in studies related to microbial resistance and oxidative stress. -
Metallo-β-lactamase Inhibitor
Metallo-β-lactamase-IN-8 is a potent reversible and competitive inhibitor of metallo-β-lactamases (MβLs), exhibiting IC50 values of 1.3 μM, 5.7 μM, 9.8 μM, and 9.9 μM against L1, ImiS, IMP-1, and VIM-2 respectively. This compound demonstrates significant antibacterial activity, making it a valuable tool for studying β-lactam resistance mechanisms in bacterial pathogens. Its ability to inhibit a broad spectrum of MβLs highlights its potential for research applications in antimicrobial resistance and drug development. -
Bacterial Inhibitor
1,4,6-Trihydroxy-5-methoxy-7-prenylxanthone is a bacterial inhibitor derived from the genus Garcinia. This compound exhibits significant antimicrobial activity against Staphylococcus aureus and Bacillus cereus, with minimum inhibitory concentration (MIC) values of 128 μg/mL and 200 μg/mL, respectively. It serves as a valuable tool in research applications aimed at understanding bacterial resistance and developing new antimicrobial therapies. -
Bacterial Inhibitor
Urease-IN-1 is a specific urease inhibitor, demonstrated by an IC50 value of 2.21 ± 0.45 µM. This compound is primarily used for research into bacterial inhibition and is relevant for studies investigating the role of urease in microbial metabolism and pathogenesis. Further applications may include exploring its potential in controlling microbial infections associated with urease-producing bacteria. -
Bacterial Inhibitor
CysHHC10 is a synthetic antimicrobial peptide that acts as a bacterial inhibitor by disrupting the integrity of microbial membranes. This compound demonstrates potent antibacterial activity against a range of both Gram-positive and Gram-negative bacteria, with minimum inhibitory concentrations (MIC) of 10.1 mM for E. coli, 20.2 mM for P. aeruginosa, 2.5 mM for S. aureus, and 1.3 mM for S. epidermidis. CysHHC10 is valuable for research applications focused on combating bacterial infections and studying microbial resistance mechanisms.
